Spain / Entering the COVID-19 Vaccine Race Through Animal Health Champion
The Spanish pharma industry has entered the race to develop COVID-19 vaccines through an unexpected contender: an…
Biogen Idec Spain
Last updated: 12.03.2014
Company Description
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Iberia, S.L.
Paseo de la Castellana 41 – 3a
28046 Madrid
Spain
Phone: +34 91 310 71 10
Fax: +34 91 310 71 11
www.biogenidec.es
Related
Spain / Grifols Invests in Nigerian Manufacturing; Almirall Nabs EMA Approval for AK Treatment; Zendal TB Vaccine Candidate Trials
The latest from Spanish pharma, including the Patent and Trademark Office’s warning of the importance of IP…
Spain / Market Growth; Esteve’s US Expansion; PTS Acquisition
The latest from Spanish pharma, including the acquisition of PTS by a private equity group for its nanoparticle…
Spain / Grifols looks to Egypt; New Leadership Generation at Almirall; Ferrer’s EIB Loan; Esteve’s European Expansion
The latest from Spanish pharma, including the wide swathe of COVID-19 syringes, vaccines, masks, and tests being…
Spain / Pharma News Roundup September 2020
A roundup of the latest news from Spanish pharma, including J&J’s COVID-19 vaccine trial, the latest…
COVID-19 / Spain’s PharmaMar to Begin Trials for Aplidin
PharmaMar, a Spanish firm, is beginning Phase II clinical trials for its anti-tumour drug Aplidin to treat…
Report / New Spain Pharma Report September 2019 Out Now
Building on the topics covered in our March 2019 report, the latest edition of Healthcare & Life Sciences…
Juan Carlos Moro Rodríguez – CEO Iberia Cluster, DB Schenker
Juan Carlos Moro Rodríguez, CEO for the Iberia Cluster with DB Schenker, discusses the company’s plans to expand…
Company Profile / Jazz Pharmaceuticals Spain: Playing to a Different Beat
Though still one of the younger and lesser-known outfits inhabiting the European drug development landscape,…
Specialising to Succeed in the Spanish Women’s Health Market
In what is a highly competitive and crowded women’s health field in Spain, smaller players are having to be…
Philanthropy / A Boost for Spain’s Out-of-Date Hospital Equipment
Many of the world’s mega-rich are increasingly active philanthropists in the healthcare arena and Spain is no…
Profile / Aspen Spain: Thriving on Change
The global acquisition of GSK’s thrombosis portfolio and subsequent purchase of AstraZeneca’s anaesthesia…
